Sugi Predict

Sugi Predict / Compounds / SCHEMBL5385142

SCHEMBL5385142

SCHEMBL5385142

CN(C)C(=O)n1cnc(S(=O)(=O)Cc2ccc(C(C)(C)C)cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1G O43497 1/20 0.36
▸ CACNA1H O95180 1/20 0.36
▸ CACNA1I Q9P0X4 1/20 0.36
▸ NR1H4 Q96RI1 3/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ RAB9A P51151 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ABCC8 Q09428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376966 0.85 DAGLA (0.43) DPP4NPC1MAPTKMT2A
SCHEMBL5384749 0.81 DPP4 (0.40) DPP4
SCHEMBL5376197 0.72 DPP4 (0.40) DPP4
SCHEMBL5380486 0.70 DPP4 (0.42) DPP4
SCHEMBL5384803 0.67 KMT2A (0.44) L3MBTL1DPP4PTGDR2LMNAALDH1A1
SCHEMBL5381808 0.67 DPP4 (0.43) EPHX2DPP4LMNAALDH1A1NPSR1
SCHEMBL5376525 0.64 KDM4E (0.40) DPP4MAPTHTTKMT2A
SCHEMBL4403151 0.64 KCNH2 (0.44) NR1H4EPHX2LMNAHDAC8ALDH1A1
SCHEMBL5385134 0.63 SCN4A (0.39) CACNA1GCACNA1HCACNA1IDPP4HDAC8
SCHEMBL5384535 0.63 DPP4 (0.50) DPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 — — US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 — — US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 — — EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 — — EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 — — US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 — — US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 CACNA1G 1540/4885CACNA1H 1838/4885CACNA1I 481/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 CACNA1G 1540/4885CACNA1H 1838/4885CACNA1I 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.